Expression of NK-associated receptors on cytotoxic T cells from melanoma patients: A two-edged sword?

Cancer Immunology, Immunotherapy

Volumn 53, Issue 10, 2004, Pages 911-924

  Tarazon, Raquel ^a   Casado, Javier G ^b   Soto, Rocío ^c   DelaRosa, Olga ^b   Peralbo, Esther ^b   Rioja, Luis ^c   Peña, José ^b   Solana, Rafael ^b  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

CD28; CD94 NKG2; Costimulation; KIR; NKR; Tumor escape; Tumor immunity

Indexed keywords

T LYMPHOCYTE RECEPTOR;

ANTIGEN RECOGNITION; CELL FUNCTION; CONFERENCE PAPER; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; MELANOMA; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY;

ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; CELL DIFFERENTIATION; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC SURVEILLANCE; LYMPHOCYTE ACTIVATION; MELANOMA; MEMBRANE GLYCOPROTEINS; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR ESCAPE;

EID: 4744365860     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0507-y     Document Type: Conference Paper

References (148)

1. Anegon I, Cuturi MC, Trinchieri G, Perussia B (1988) Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med 167:452
2. Anichini A, Molla A, Mortarini R, Tragni G, Bersani I, Di Nicola M, Gianni AM, Pilotti S, Dunbar R, Cerundolo V, Parmiani G (1991) An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 190:651
3. Anichini A, Scarito A, Molla A, Parmiani G, Mortarini R (2003) Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines. J Immunol 171:2134
4. Arase N, Arase H, Park SY, Ohno H, Ra C, Saito T (1997) Association with FcRgamma is essential for activation signal through NKR-P1 (CD161) in natural killer (NK) cells and NK1.1+ T cells. J Exp Med 186:1957
5. Azzoni L, Zatsepina O, Abebe B, Bennett IM, Kanakaraj P, Perussia B (1998) Differential transcriptional regulation of CD161 and a novel, 197/15a, by IL-2, IL-15, and IL-12 in NK and T cells. J Immunol 161:3493
6. Bakker AB, Phillips JH, Figdor CG, Lanier LL (1998) Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. J Immunol 160:5239
7. Baron V, Bouneaud C, Cumano A, Lim A, Arstila TP, Kourilsky P, Ferradini L, Pannetier C (2003) The repertoires of circulating human CD8(+) central and effector memory T cell subsets are largely distinct. Immunity 18:193
8. Barzegar C, Meazza R, Pereno R, Pottin-Clemenceau C, Scudeletti M, Brouty-Boye D, Doucet C, Taoufik Y, Ritz J, Musselli C, Mishal Z, Jasmin C, Indiveri F, Ferrini S, Azzarone B (1998) IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through j uxtacrine loops. Oncogene 16:2503
9. Becker JC, Brocker EB (1995) Lymphocyte-melanoma interaction: role of surface molecules. Recent Results Cancer Res 139:205
10. Becker JC, Brabletz T, Czerny C, Termeer C, Brocker EB (1993) Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. Int Immunol 5:1501
11. Bernsen MR, Hakansson L, Gustafsson B, Krysander L, Rettrup B, Ruiter D, Hakansson A (2003) On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases. Br J Cancer 88:424
12. Bertone S, Schiavetti F, Bellomo R, Vitale C, Ponte M, Moretta L, Mingari MC (1999) Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur J Immunol 29:23
13. Borrego F, Kabat J, Kim DK, Lieto L, Maasho K, Pena J, Solana R, Coligan JE (2002) Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol 38:637
14. Brady MS, Lee F, Eckels DD, Ree SY, Latouche JB, Lee JS (2000) Restoration of alloreactivity of melanoma by transduction with B7.1. J Immunother 23:353
15. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, Casazza JP, Kuruppu J, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA (2003) Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101:2711
16. Brown MH, Boles K, van der Merwe PA, Kumar V, Mathew PA, Barclay AN (1998) 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med 188:2083
17. Bullock TN, Mullins DW, Colella TA, Engelhard VH (2001) Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice. J Immunol 167:5824
18. Carreno BM, Collins M (2002) The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 20:29
19. Casado JG, DelaRosa O, Peralbo E, Tarazona R, Solana R (2003) CD28 downregulation and expression of NK associated receptors on T cells in aging and situations of chronic activation of the immune system. In: Pawelec G (ed) Basic biology and clinical impact of immunosenescence. Elsevier, Amsterdam, p 123
20. Chambers CA, Kuhns MS, Egen JG, Allison JP (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565
21. Chuang SS, Kim MH, Johnson LA, Albertsson P, Kitson RP, Nannmark U, Goldfarb RH, Mathew PA (2000) 2B4 stimulation of YT cells induces natural killer cell cytolytic function and invasiveness. Immunology 100:378
22. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV (1998) Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A 95:652
23. Cookson S, Reen D (2003) IL-15 drives neonatal T cells to acquire CD56 and become activated effector cells. Blood 102:2195
24. Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633
25. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ (2001) ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123
26. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M, Taniguchi M (1997) Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623
27. D'Andrea A, Chang C, Phillips JH, Lanier LL (1996) Regulation of T cell lymphokine production by killer cell inhibitory receptor recognition of self HLA class I alleles. J Exp Med 184:789
28. De Maria A, Moretta L (2000) HLA-class I-specific inhibitory receptors in HIV-1 infection. Hum Immunol 61:74
29. DelaRosa O, Tarazona R, Casado JG, Alonso C, Ostos B, Pena J, Solana R (2002) Valpha24+ NKT cells are decreased in elderly humans. Exp Gerontol 37:213
30. Denfeld RW, Dietrich A, Wuttig C, Tanczos E, Weiss JM, Vanscheidt W, Schopf E, Simon JC (1995) In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity. Int J Cancer 62:259
31. Derre L, Corvaisier M, Pandolfino MC, Diez E, Jotereau F, Gervois N (2002) Expression of CD94/NKG2-A on human T lymphocytes is induced by IL-12: implications for adoptive immunotherapy. J Immunol 168:4864
32. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793
33. Dunbar PR, Smith CL, Chao D, Salio M, Shepherd D, Mirza F, Lipp M, Lanzavecchia A, Sallusto F, Evans A, Russell-Jones R, Harris AL, Cerundolo V (2000) A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol 165:6644
34. Fenton RG, Turcovski-Corrales SM, Taub DD (1998) Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines. J Immunother 21:95
35. Ferrone S, Finerty JF, Jaffee EM, Nabel GJ (2000) How much longer will tumour cells fool the immune system? Immunol Today 21:70
36. Frauwirth KA, Thompson CB (2002) Activation and inhibition of lymphocytes by costimulation. J Clin Invest 109:295
37. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG (2000) NKT cells: facts, functions and fallacies. Immunol Today 21:573
38. Gritzapis AD, Dimitroulopoulos D, Paraskevas E, Baxevanis CN, Papamichail M (2002) Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunol Immunother 51:440
39. Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734
40. Guarini A, Riera L, Cignetti A, Montacchini L, Massaia M, Foa R (1997) Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. Blood 89:212
41. Guerra N, Benlhassan K, Carayol G, Guillard M, Pardoux C, Chouaib S, Caignard A (1999) Effect of tumor growth factor-beta on NK receptor expression by allostimulated CD8+ T lymphocytes. Eur Cytokine Netw 10:357
42. Gunturi A, Berg RE, Forman J (2003) Preferential survival of CD8 T and NK cells expressing high levels of CD94. J Immunol 170:1737
43. Hakansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Hakansson L (1999) On down-regulation of the immune response to metastatic malignant melanoma. Cancer Immunol Immunother 48:253
44. Hakansson A, Hakansson L, Gustafsson B, Krysander L, Rettrup B, Ruiter D, Bernsen MR (2002) Biochemotherapy of metastatic malignant melanoma: on down-regulation of CD28. Cancer Immunol Immunother 51:499
45. Hammond KJ, Pelikan SB, Crowe NY, Randle-Barrett E, Nakayama T, Taniguchi M, Smyth MJ, van Driel IR, Scollay R, Baxter AG, Godfrey DI (1999) NKT cells are phenotypically and functionally diverse. Eur J Immunol 29:3768
46. Heinzel S, Rea D, Offringa R, Pawelec G (2001) The self peptide annexin II (208-223) presented by dendritic cells sensitizes autologous CD4+ T lymphocytes to recognize melanoma cells. Cancer Immunol Immunother 49:671
47. Held W, Coudert JD, Zimmer J (2003) The NK cell receptor repertoire: formation, adaptation and exploitation. Curr Opin Immunol 15:233
48. Hersey P, Si Z, Smith MJ, Thomas WD (1994) Expression of the co-stimulatory molecule B7 on melanoma cells. Int J Cancer 58:527
49. Hom SS, Schwartzentruber DJ, Rosenberg SA, Topalian SL (1993) Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J Immunother 13:18
50. Houghton AN, Gold JS, Blachere NE (2001) Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 13:134
51. Huard B, Karlsson L (2000) A subpopulation of CD8+ T cells specific for melanocyte differentiation antigens expresses killer inhibitory receptors (KIR) in healthy donors: evidence for a role of KIR in the control of peripheral tolerance. Eur J Immunol 30:1665
52. Huttenbach Y, Prieto VG, Reed JA (2002) Desmoplastic and spindle cell melanomas express protein markers of the neural crest but not of later committed stages of Schwann cell differentiation. J Cutan Pathol 29:562
53. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, De Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199
54. Imaizumi K, Kawabe T, Ichiyama S, Kikutani H, Yagita H, Shimokata K, Hasegawa Y (1999) Enhancement of tumoricidal activity of alveolar macrophages via CD40-CD40 ligand interaction. Am J Physiol 277:L49-L57
55. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99:12293
56. Jager E, Hohn H, Necker A, Forster R, Karbach J, Freitag K, Neukirch C, Castelli C, Salter RD, Knuth A, Maeurer MJ (2002) Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1. Int J Cancer 98:376
57. Jan CN, Sutherland CL, Lawrence WA, Rein-Weston A, Cosman D (2003) ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun 305:129
58. Jaques AJ, Opdenakker G, Rademacher TW, Dwek RA, Zamze SE (1996) The glycosylation of Bowes melanoma tissue plasminogen activator: lectin mapping, reaction with anti-L2/ HNK-1 antibodies and the presence of sulphated/glucuronic acid containing glycans. Biochem J 316 (Pt 2):427
59. Johnson LA, Goldfarb RH, Mathew PA (2000) Regulation of IFN-gamma production following 2B4 activation in human NK cells. In Vivo 14:625
60. Jovic V, Konjevic G, Radulovic S, Jelic S, Spuzic I (2001) Impaired perforin-dependent NK cell cytotoxicity and proliferative activity of peripheral blood T cells is associated with metastatic melanoma. Tumori 87:324
61. Kambayashi T, Assarsson E, Chambers BJ, Ljunggren HG (2001) Cutting edge: Regulation of CD8(+) T cell proliferation by 2B4/CD48 interactions. J Immunol 167:6706
62. Karlhofer FM, Ribaudo RK, Yokoyama WM (1992) MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 358:66
63. Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675
64. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, Kondo E, Harada M, Koseki H, Nakayama T, Tanaka Y, Taniguchi M (1998) Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci U S A 95:5690
65. Kawano T, Nakayama T, Kamada N, Kaneko Y, Harada M, Ogura N, Akutsu Y, Motohashi S, Iizasa T, Endo H, Fujisawa T, Shinkai H, Taniguchi M (1999) Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 59:5102
66. Kikuchi A, Nieda M, Schmidt C, Koezuka Y, Ishihara S, Ishikawa Y, Tadokoro K, Durrant S, Boyd A, Juji T, Nicol A (2001) In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+ NKT cells against melanoma. Br J Cancer 85:741
67. Kubin MZ, Parshley DL, Din W, Waugh JY, Davis-Smith T, Smith CA, Macduff BM, Armitage RJ, Chin W, Cassiano L, Borges L, Petersen M, Trinchieri G, Goodwin RG (1999) Molecular cloning and biological characterization of NK cell activation-inducing ligand, a counterstructure for CD48. Eur J Immunol 29:3466
68. Lanier LL, Chang C, Azuma M, Ruitenberg JJ, Hemperly JJ, Phillips JH (1991) Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56). J Immunol 146:4421
69. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH (1998) Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391:703
70. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677
71. Letsch A, Keilholz U, Assfalg G, Mailander V, Thiel E, Scheibenbogen C (2003) Bone marrow contains melanoma-reactive CD8+ effector T cells and, compared with peripheral blood, enriched numbers of melanoma-reactive CD8+ memory T cells. Cancer Res 63:5582
72. Li K, Adibzadeh M, Halder T, Kalbacher H, Heinzel S, Muller C, Zeuthen J, Pawelec G (1998) Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother 47:32
73. Li Y, Hellstrom KE, Newby SA, Chen L (1996) Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med 183:639
74. Li Y, McGowan P, Hellstrom I, Hellstrom KE, Chen L (1994) Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 153:421
75. Liu X, Bai XF, Wen J, Gao JX, Liu J, Lu P, Wang Y, Zheng P, Liu Y (2001) B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo. J Exp Med 194:1339
76. Maio M, Fonsatti E, Lamaj E, Altomonte M, Cattarossi I, Santantonio C, Melani C, Belli F, Arienti F, Colombo MP, Parmiani G (2002) Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother 51:9
77. Marin R, Ruiz-Cabello F, Pedrinaci S, Mendez R, Jimenez P, Geraghty DE, Garrido F (2003) Analysis of HLA-E expression in human tumors. Immunogenetics 54:767
78. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S (2003) Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 24:335
79. Mazzocchi A, Melani C, Rivoltini L, Castelli C, Del Vecchio M, Lombardo C, Colombo MP, Parmiani G (2001) Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes. Cancer Immunol Immunother 50:199
80. McCarthy DO, Glowacki N, Schell K, Emler CA, Albertini MR (2000) Antigenicity of human melanoma cells transfected to express the B7-1 co-stimulatory molecule (CD80) varies with the level of B7-1 expression. Cancer Immunol Immunother 49:85
81. McQueen KLParham P (2002) Variable receptors controlling activation and inhibition of NK cells. Curr Opin Immunol 14:615
82. Menier C, Riteau B, Carosella ED, Rouas-Freiss N (2002) MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int J Cancer 100:63
83. Merino J, Martinez-Gonzalez MA, Rubio M, Inoges S, Sanchez-Ibarrola A, Subira ML (1998) Progressive decrease of CD8high+ CD28+ CD57- cells with ageing. Clin Exp Immunol 112:48
84. Mingari MC, Schiavetti F, Ponte M, Vitale C, Maggi E, Romagnani S, Demarest J, Pantaleo G, Fauci AS, Moretta L (1996) Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc Natl Acad Sci U S A 93:12433
85. Mingari MC, Ponte M, Bertone S, Schiavetti F, Vitale C, Bellomo R, Moretta A, Moretta L (1998) HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells. Proc Natl Acad Sci U S A 95:1172
86. Mingari MC, Ponte M, Vitale C, Bellomo R, Moretta L (2000) Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function. Hum Immunol 61:44
87. Moretta A, Moretta L (1997) HLA class I specific inhibitory receptors. Curr Opin Immunol 9:694
88. Moretta A, Vitale M, Bottino C, Orengo AM, Morelli L, Augugliaro R, Barbaresi M, Ciccone E, Moretta L (1993) P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 178:597
89. Moretta A, Sivori S, Vitale M, Pende D, Morelli L, Augugliaro R, Bottino C, Moretta L (1995) Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 182:875
90. Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A (2003) Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 63:2535
91. Nakajima H, Cella M, Langen H, Friedlein A, Colonna M (1999) Activating interactions in human NK cell recognition: the role of 2B4-CD48. Eur J Immunol 29:1676
92. Namekawa T, Snyder MR, Yen JH, Goehring BE, Leibson PJ, Weyand CM, Goronzy JJ (2000) Killer cell activating receptors function as costimulatory molecules on CD4+CD28null T cells clonally expanded in rheumatoid arthritis. J Immunol 165:1138
93. Nitta T, Yagita H, Sato K, Okumura K (1989) Involvement of CD56 (NKH-1/Leu-19 antigen) as an adhesion molecule in natural killer-target cell interaction. J Exp Med 170:1757
94. Palmowski M, Salio M, Dunbar RP, Cerundolo V (2002) The use of HLA class I tetramers to design a vaccination strategy for melanoma patients. Immunol Rev 188:155
95. Park SH, Kyin T, Bendelac A, Carnaud C (2003) The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J Immunol 170:1197
96. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, Schrader S, Burkhead S, Heipel M, Brandt C, Kuijper JL, Kramer J, Conklin D, Presnell SR, Berry J, Shiota F, Bort S, Hambly K, Mudri S, Clegg C, Moore M, Grant FJ, Lofton-Day C, Gilbert T, Rayond F, Ching A, Yao L, Smith D, Webster P, Whitmore T, Maurer M, Kaushansky K, Holly RD, Foster D (2000) Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408:57
97. Paschen A, Mendez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D (2003) Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 103:759
98. Pedersen LO, Vetter CS, Mingari MC, Andersen MH, thor SP, Brocker EB, Becker JC (2002) Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: a case report. J Invest Dermatol 118:595
99. Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, Nanni M, Biassoni R, Bottino C, Moretta A, Moretta L (2001) Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31:1076
100. Peritt D, Sesok-Pizzini DA, Schretzenmair R, Macgregor RR, Valiante NM, Tu X, Trinchieri G, Kamoun M (1999) C1.7 antigen expression on CD8+ T cells is activation dependent: increased proportion of C1.7+CD8+ T cells in HIV-1-infected patients with progressing disease. J Immunol 162:7563
101. Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P (2000) Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 164:1148
102. Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN (2003) Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 22:3180
103. Raulet DH (2003) Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3:781
104. Real LM, Jimenez P, Kirkin A, Serrano A, Garcia A, Canton J, Zeuthen J, Garrido F, Ruiz-Cabello F (2001) Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol Immunother 49:621
105. Reed JA, Finnerty B, Albino AP (1999) Divergent cellular differentiation pathways during the invasive stage of cutaneous malignant melanoma progression. Am J Pathol 155:549
106. Romero P, Ortega C, Palma A, Molina IJ, Pena J, Santamaria M (2001) Expression of CD94 and NKG2 molecules on human CD4(+) T cells in response to CD3-mediated stimulation. J Leukoc Biol 70:219
107. Rowbottom AW, Garland RJ, Lepper MW, Kaneria SS, Goulden NJ, Oakhill A, Steward CG (2000) Functional analysis of the CD8+CD57+ cell population in normal healthy individuals and matched unrelated T-cell-depleted bone marrow transplant recipients. Br J Haematol 110:315
108. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708
109. Schwartzentruber DJ, Topalian SL, Mancini M, Rosenberg SA (1991) Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J Immunol 146:3674
110. Seliger B, Abken H, Ferrone S (2003) HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol 24:82
111. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F (2001) Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′- deoxycytidine treatment. Int J Cancer 94:243
112. Sharpe AHFreeman GJ (2002) The B7-CD28 superfamily. Nature Rev Immunol 2:116
113. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191:661
114. Snyder MR, Lucas M, Vivier E, Weyand CM, Goronzy JJ (2003) Selective activation of the c-Jun NH2-terminal protein kinase signaling pathway by stimulatory KIR in the absence of KARAP/DAP12 in CD4+ T cells. J Exp Med 197:437
115. Speiser DE, Pittet MJ, Valmori D, Dunbar R, Rimoldi D, Lienard D, MacDonald HR, Cerottini JC, Cerundolo V, Romero P (1999) In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J Exp Med 190:775
116. Speiser DE, Valmori D, Rimoldi D, Pittet MJ, Lienard D, Cerundolo V, MacDonald HR, Cerottini JC, Romero P (1999) CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Eur J Immunol 29:1990
117. Speiser DE, Colonna M, Ayyoub M, Cella M, Pittet MJ, Batard P, Valmori D, Guillaume P, Lienard D, Cerottini JC, Romero P (2001) The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells. J Immunol 167:6165
118. Speiser DE, Migliaccio M, Pittet MJ, Valmori D, Lienard D, Lejeune F, Reichenbach P, Guillaume P, Luscher I, Cerottini JC, Romero P (2001) Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells. Eur J Immunol 31:459
119. Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D (2002) UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 168:671
120. Sze DM, Giesajtis G, Brown RD, Raitakari M, Gibson J, Ho J, Baxter AG, Fazekas dSG, Basten A, Joshua DE (2001) Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood 98:2817
121. Takahashi T, Nieda M, Koezuka Y, Nicol A, Porcelli SA, Ishikawa Y, Tadokoro K, Hirai H, Juji T (2000) Analysis of human V alpha 24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 164:4458
122. Takasaki S, Hayashida K, Morita C, Ishibashi H, Niho Y (2000) CD56 directly interacts in the process of NCAM-positive target cell-killing by NK cells. Cell Biol Int 24:101
123. Tang NE, Luyten GP, Mooy CM, Naus NC, de Jong PT, Luider TM (1996) HNK-1 antigens on uveal and cutaneous melanoma cell lines. Melanoma Res 6:411
124. Tarazona R, DelaRosa O, Alonso C, Ostos B, Espejo J, Pena J, Solana R (2000) Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech Ageing Dev 121:77
125. Tarazona R, DelaRosa O, Casado JG, Torre-Cisneros J, Villanueva JL, Galiani MD, Pena J, Solana R (2002) NK-associated receptors on CD8 T cells from treatment-naive HIV-infected individuals: defective expression of CD56. AIDS 16:197
126. Tarazona R, Borrego F, Galiani MD, Aguado E, Pena J, Coligan JE, Solana R (2002) Inhibition of CD28-mediated natural cytotoxicity by KIR2DL2 does not require p56(lck) in the NK cell line YT-Indy. Mol Immunol 38:495
127. Tarazona R, Casado JG, DelaRosa O, Torre-Cisneros J, Villanueva JL, Sanchez B, Galiani MD, Gonzalez R, Solana R, Pena J (2002) Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 22:176
128. Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, Rosenberg SA (1994) Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A 91:9461
129. Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A, Rosenberg SA, Robbins PF (1996) Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 183:1965
130. Tough DF (2003) Deciphering the relationship between central and effector memory CD8+ T cells. Trends Immunol 24:404
131. Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA, Restifo NP (2000) Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol 164:3535
132. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M (1999) Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 163:2387
133. Ugolini S, Arpin C, Anfossi N, Walzer T, Cambiaggi A, Forster R, Lipp M, Toes RE, Melief CJ, Marvel J, Vivier E (2001) Involvement of inhibitory NKRs in the survival of a subset of memory-phenotype CD8+ T cells. Nat Immunol 2:430
134. Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, Rubio-Godoy V, Rimoldi D, Guillaume P, Romero P, Schadendorf D, Lipp M, Dietrich PY, Thiel E, Cerottini JC, Lienard D, Keilholz U (2002) Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 62:1743
135. Van den Hove LE, Van Gool SW, Vandenberghe P, Boogaerts MA, Ceuppens JL (1998) CD57+/CD28- T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendency to apoptosis. Leukemia 12:1573
136. Vesosky B, Hurwitz AA (2003) Modulation of costimulation to enhance tumor immunity. Cancer Immunol Immunother 52:663
137. Vetter CS, Straten PT, Terheyden P, Zeuthen J, Brocker EB, Becker JC (2000) Expression of CD94/NKG2 subtypes on tumor-infiltrating lymphocytes in primary and metastatic melanoma. J Invest Dermatol 114:941
138. Vetter CS, Groh V, thor SP, Spies T, Brocker EB, Becker JC (2002) Expression of stress-induced MHC class I related chain molecules on human melanoma. J Invest Dermatol 118:600
139. Wallin JJ, Liang L, Bakardjiev A, Sha WC (2001) Enhancement of CD8+ T cell responses by ICOS/B7 h costimulation. J Immunol 167:132
140. Warren HS, Kinnear BF (1999) Quantitative analysis of the effect of CD16 ligation on human NK cell proliferation. J Immunol 162:755
141. Watzl C, Stebbins CC, Long EO (2000) NK cell inhibitory receptors prevent tyrosine phosphorylation of the activation receptor 2B4 (CD244). J Immunol 165:3545
142. Weekes MP, Wills MR, Mynard K, Hicks R, Sissons JG, Carmichael AJ (1999) Large clonal expansions of human virus-specific memory cytotoxic T lymphocytes within the CD57+ CD28- CD8+ T-cell population. Immunology 98:443
143. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R (2003) Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4:225
144. Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB (2003) Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 198(1):173-181
145. Wu J, Lanier LL (2003) Natural killer cells and cancer. Adv Cancer Res 90:127
146. Yokoyama WM, Plougastel BF (2003) Immune functions encoded by the natural killer gene complex. Nat Rev Immunol 3:304
147. Young NT, Uhrberg M, Phillips JH, Lanier LL, Parham P (2001) Differential expression of leukocyte receptor complex-encoded Ig-like receptors correlates with the transition from effector to memory CTL. J Immunol 166:3933
148. Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers GC, Urba WJ (1995) Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1:1327